Family 1 Priority Date Sept 2010
Covers all prothrombin activators derived from snake venom including naturally- occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.
July 2017: Patent granted in EU, Japan and Australia. Other jurisdictions progressing.
Family 2 Priority Date Oct 2014
'Improved Clotting Composition'
Covers formulations to enhance the temperature and irradiation stability of snake venom-derived prothrombin activators in blood collection tubes.
National Phase commenced.